Eli Lilly and Company (LLY) FCF Payout Ratio: 42.72%
Is Eli Lilly and Company’s FCF payout ratio high or low?
Eli Lilly and Company's FCF payout ratio of 42.72% is 85% below its 5-year average of 276.80%, near the low end of its 5-year range (57.30%–1129.71%).
The FCF payout ratio for Eli Lilly and Company (LLY) is 42.72%. It is below its 12-month average by 92.82% (594.86%).
LLY FCF Payout Ratio Chart
LLY Average FCF Payout Ratio Chart
LLY Current vs Average FCF Payout Ratio Chart
LLY FCF Payout Ratio Metrics
FCF PAYOUT RATIO
42.72%
FCF PAYOUT RATIO AVG TTM
594.86%
FCF PAYOUT RATIO AVG 3Y
422.19%
FCF PAYOUT RATIO AVG 5Y
276.80%
FCF PAYOUT RATIO AVG 10Y
182.53%
FCF PAYOUT RATIO AVG 15Y
138.17%
FCF PAYOUT RATIO AVG 20Y
127.05%
CURRENT VS TTM AVG
-92.82%
CURRENT VS 3Y AVG
-89.88%
CURRENT VS 5Y AVG
-84.57%
CURRENT VS 10Y AVG
-76.60%
CURRENT VS 15Y AVG
-69.08%
CURRENT VS 20Y AVG
-66.38%
Payout Ratio Comparison
FCF Payout Ratio
42.7%
Earnings Payout Ratio
28.1%
Dividend Yield
0.57%
FCF Yield
1.33%
Annual FCF Payout Ratio History
| Year | Free Cash Flow | Dividends Paid | FCF Payout Ratio |
|---|---|---|---|
| 2025 | $8.97B | $5.38B | 60.0% |
| 2024 | $414.30M | $4.68B | 1129.7% |
| 2023 | ($3.15B) | $4.07B | N/A (Loss) |
| 2022 | $4.60B | $3.54B | 76.9% |
| 2021 | $5.39B | $3.09B | 57.3% |
| 2020 | $4.47B | $2.69B | 60.1% |
| 2019 | $3.48B | $2.41B | 69.2% |
| 2018 | $2.51B | $2.31B | 92.2% |
| 2017 | $3.45B | $2.19B | 63.5% |
| 2016 | $3.76B | $2.16B | 57.4% |
| 2015 | $1.34B | $2.13B | 158.9% |
| 2014 | $2.89B | $2.10B | 72.6% |
| 2013 | $4.64B | $2.12B | 45.7% |
| 2012 | $4.26B | $2.19B | 51.3% |
| 2011 | $5.54B | $2.18B | 39.3% |
| 2010 | $5.67B | $2.17B | 38.2% |
| 2009 | $3.48B | $2.15B | 61.8% |
| 2008 | $6.35B | $2.06B | 32.4% |
| 2007 | $4.07B | $1.85B | 45.5% |
| 2006 | $2.90B | $1.74B | 59.9% |
| 2005 | $615.50M | $1.65B | 268.9% |
| 2004 | $971.40M | $1.54B | 158.5% |
| 2003 | $1.94B | $1.44B | 74.4% |
| 2002 | $939.80M | $1.34B | 142.1% |
| 2001 | $2.78B | $1.21B | 43.5% |
| 2000 | $3.05B | $1.13B | 36.9% |
| 1999 | $2.09B | $1.00B | 47.8% |
| 1998 | $2.21B | $877.70M | 39.7% |
| 1997 | $2.03B | $818.00M | 40.2% |
| 1996 | $1.55B | $753.20M | 48.7% |
Formula: FCF Payout Ratio = Dividends Paid / Free Cash Flow × 100
FCF payout and earnings payout:
- FCF represents operating cash flow after capital expenditures
- FCF payout compares dividends paid with free cash flow
- FCF payout above 100% means dividends paid exceeded free cash flow for the period
- Earnings payout compares dividends paid with net income
Reading the series: Use the chart and table to compare dividend payments with cash generation over time.
Eli Lilly and Company FCF Payout Ratio Formula & Definition
FCF Payout Ratio measures what percentage of free cash flow is paid out as dividends. Unlike earnings-based payout, it compares dividends with cash generated after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Eli Lilly and Company FCF Payout Ratio FAQ
- What is the FCF payout ratio for Eli Lilly and Company (LLY)?
- The FCF payout ratio for LLY stock is 42.72%.
- Is Eli Lilly and Company's FCF payout ratio high or low?
- Eli Lilly and Company's FCF payout ratio of 42.72% is 85% below its 5-year average of 276.80%, near the low end of its 5-year range (57.30%–1129.71%).
- What is the TTM average FCF payout ratio for Eli Lilly and Company (LLY)?
- The TTM average FCF payout ratio for LLY stock is 594.86%.
- What is the 3Y average FCF payout ratio for Eli Lilly and Company (LLY)?
- The 3Y average FCF payout ratio for LLY stock is 422.19%.
- What is the 5Y average FCF payout ratio for Eli Lilly and Company (LLY)?
- The 5Y average FCF payout ratio for LLY stock is 276.80%.
- What is the 10Y average FCF payout ratio for Eli Lilly and Company (LLY)?
- The 10Y average FCF payout ratio for LLY stock is 182.53%.
- What is the 15Y average FCF payout ratio for Eli Lilly and Company (LLY)?
- The 15Y average FCF payout ratio for LLY stock is 138.17%.
- What is the 20Y average FCF payout ratio for Eli Lilly and Company (LLY)?
- The 20Y average FCF payout ratio for LLY stock is 127.05%.
Eli Lilly and Company FCF Payout Ratio History
| DATE | FCF PAYOUT RATIO |
|---|---|
| 2025-12-31 | 60.01% |
| 2024-12-31 | 1129.71% |
| 2022-12-31 | 76.86% |
| 2021-12-31 | 57.30% |
| 2020-12-31 | 60.11% |
| 2019-12-31 | 69.19% |
| 2018-12-31 | 92.24% |
| 2017-12-31 | 63.50% |
| 2016-12-31 | 57.42% |
| 2015-12-31 | 158.94% |
| 2014-12-31 | 72.64% |
| 2013-12-31 | 45.69% |
| 2012-12-31 | 51.34% |
| 2011-12-31 | 39.34% |
| 2010-12-31 | 38.19% |
| 2009-12-31 | 61.83% |
| 2008-12-31 | 32.40% |
| 2007-12-31 | 45.52% |
| 2006-12-31 | 59.91% |
| 2005-12-31 | 268.87% |
| 2004-12-31 | 158.51% |
| 2003-12-31 | 74.38% |
| 2002-12-31 | 142.14% |
| 2001-12-31 | 43.46% |
| 2000-12-31 | 36.87% |
| 1999-12-31 | 47.84% |
| 1998-12-31 | 39.72% |
| 1997-12-31 | 40.21% |
| 1996-12-31 | 48.67% |
About Eli Lilly and Company
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal and various head and neck cancers; Retevmo, used in metastatic NSCLC, medullary thyroid, and other thyroid cancers; Tyvyt for relapsed or refractory classic Hodgkin's lymphoma and non-squamous NSCLC; and Verzenio, prescribed for HR+, HER2- metastatic breast cancer, node-positive, and early breast cancer. For autoimmune and inflammatory conditions, the company markets Olumiant for rheumatoid arthritis, and Taltz, which addresses plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Addressing neurological and pain management needs, Eli Lilly provides Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain. Emgality is available for migraine prevention and episodic cluster headaches, while Zyprexa treats schizophrenia, bipolar I disorder, and aids in bipolar maintenance. Other significant products include Bamlanivimab and etesevimab, along with Bebtelovimab, both developed for COVID-19. Cialis is offered for erectile dysfunction and benign prostatic hyperplasia, and Forteo is available for osteoporosis. Eli Lilly actively engages in strategic collaborations with numerous partners, including Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Established in 1876, Eli Lilly and Company maintains its corporate headquarters in Indianapolis, Indiana.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- David A. Ricks